Presented by
Today's News Recap
Sit-downs Scheduled - SEC plans 4 more crypto roundtables on trading, custody, tokenization, and DeFi.
Stablecoin Coming Soon - Fidelity developing stablecoin as part of tokenized fund push.
Follow-Up Fund - BlackRock launches Bitcoin fund in Europe following IBIT success.
New here? Ask Copilot up to 2 free queries per day with Messari Basic.
Top Assets
Messari Quarterly Reports
Messari's protocol reports give you a deep dive on the foundation and state of top crypto protocols, including key metrics and notable events. See the complete list of protocol reports here and get a preview of our latest report below.
From Our Sponsor
The power of tomorrow, tokenized.
Uranium.io is the world's first platform for trading uranium, powered by Tezos. ⚡️
Unlike gold or silver, uranium’s market has high barriers to entry, with minimum order sizes of millions of dollars and thousands of lbs.
Tokenized uranium lowers these barriers, making ownership accessible without complex storage. Uranium, the asset powering the AI revolution, is now widely accessible. 🌍
Learn more at https://uranium.io/
Messari Research
Bio Protocol V1 Upgrade: Scaling DeSci's Financial Layer
By: Chris Davis
Bio V1 represents a major evolution in Bio Protocol's development, transforming the protocol from a high-touch, centralized accelerator into a permissionless, scalable financial layer. The upgrade introduces three core components: a Launchpad for onboarding new BioDAOs, a fleet of decentralized AI research agents (BioAgents), and milestone-based incentives to align funding with scientific output. BioAgents reduce the time and cost to generate monetizable IP, dramatically improving BioDAO efficiency and capital allocation dynamics.
The BIO token now plays a central utility role—used for staking, curation, agent operations, and liquidity—broadening its demand profile beyond governance.
V1 also diversifies Bio Protocol’s revenue across four verticals: asset management, fundraising fees, liquidity provision, and agent services, shifting its valuation model from treasury-based to sum-of-parts. These changes position Bio Protocol to become a self-sustaining system that scales with minimal overhead. For capital allocators, the result is a more attractive, lower-risk environment for funding decentralized science.
